Effect of macrotroponin on the utility of cardiac troponin I as a prognostic biomarker for long term total and cardiovascular disease mortality
| Autor: | Patrick Gladding, Leah Ha, Rexson Tse, Leo Lam, Campbell Kyle |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Pathology and Forensic Medicine Cohort Studies Interquartile range Internal medicine Troponin I Medicine Humans Clinical significance health care economics and organizations Aged Aged 80 and over biology business.industry Hazard ratio Autoantibody Middle Aged Prognosis Troponin Cardiovascular Diseases Cohort biology.protein Cardiology Biomarker (medicine) Female business Biomarkers |
| Zdroj: | Pathology. 53(7) |
| ISSN: | 1465-3931 |
| Popis: | Macrotroponin is a complex formed between endogenous cardiac troponin autoantibodies and circulating cardiac troponin (cTn). It is a recognised cause of discrepancy between current high sensitivity troponin (hs-cTn) assays; and immunoglobulin-bound (macrotroponin) and unbound cTn can coexist in varying proportions in the acute setting. Increasingly it is considered when laboratory cTn results do not match a patient's clinical picture. However, despite the better understanding of macrotroponin as an analytical interference, its clinical significance remains unclear. The aim of this study was to determine the potential impact of macrotroponin on the use of cTn as a long-term prognostic marker. We repeated cTnI testing after polyethylene glycol (PEG) precipitation on consecutive participants (n=159) with a first elevated cTn above 0.2 μg/L during their hospital admission episode. Because this paper is looking at outcomes in years, the initial data were generated at a time when non-hs-cTn assays were in use. We divided the cohort into two groups based on an exploratory PEG recovery cut-off of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect